Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies

Roman Generalov, Elisa Fiorito, Stian Foss, Veronique Pascal, Helen Heyerdahl, Ada Repetto-Llamazares, Jan Terje Andersen, Geir E Tjønnfjord, Sigrid Strand Skånland, Jostein Dahle

Blood (2022) 140 (Supplement 1): 3123–3124.

https://doi.org/10.1182/blood-2022-166275

Published: 2022

Journal Articles

B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life

Elisa Fiorito, Roman Generalov, Stian Foss, Helen Heyerdahl, Ada Repetto-Llamazares, Veronique Pascal, Geir E Tjønnfjord, Sigrid Strand Skånland, Jan Terje Andersen, Jostein Dahle

Blood (2022) 140 (Supplement 1): 6012–6013.

https://doi.org/10.1182/blood-2022-159382

Published: 2022

Journal Articles

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Tara Helen Dowling Dowling Steinsland, MSc, Stein-Erik Gullaksen, MS, PhD, Geir Bredholt, PhD, Calum Leitch, PhD, Mireia Mayoral Safont, BS, Øystein Bruserud, MD PhD, Mihaela Popa, Astri Maaland, Helen Heyerdahl, PhD, Jostein Dahle, PhD, Bjorn T. Gjertsen, MD PhD, Emmet Mccormack, BSc, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142899

Published: 2020

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Amal Saidi, PhD, Astri Maaland, Julien Torgue, PhD, Helen Heyerdahl, PhD, Jostein Dahle, PhD

Blood (2018) 132 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2018-99-110297

Published: 2018

Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2018) 132 (Supplement 1): 1371.

https://doi.org/10.1182/blood-2018-99-110200

Published: 2018

Journal Articles

Combination of 177 lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma

Ada H.V. Repetto-Llamazares, PhD, Roy Hartvig Larsen, PhD, Adam O'Shea, Jostein Dahle

Blood (2016) 128 (22): 4189.

https://doi.org/10.1182/blood.V128.22.4189.4189

Published: 2016

Journal Articles

The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177 lu-Satetraxetan-Lilotomab

Arne Kolstad, MD PhD, Matthew Beasley, Michael Bayne, Ingemar Lagerlöf, Noelle O'Rourke, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Simon Turner, Roy Hartvig Larsen, Harald Holte

Blood (2016) 128 (22): 5339.

https://doi.org/10.1182/blood.V128.22.5339.5339

Published: 2016

Journal Articles

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Blood (2016) 128 (22): 1780.

https://doi.org/10.1182/blood.V128.22.1780.1780

Published: 2016

Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD

Blood (2015) 126 (23): 5118.

https://doi.org/10.1182/blood.V126.23.5118.5118

Published: 2015

Journal Articles

Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo

Ada H.V. Repetto-Llamazares, PhD, Roy Hartvig Larsen, PhD, Landsverk Kirsti, PhD, Trond Stokke, PhD, Bergthora Eiriksdottir, PhD, Roman Generalov, MSc, Jostein Dahle, PhD

Blood (2015) 126 (23): 3245.

https://doi.org/10.1182/blood.V126.23.3245.3245

Published: 2015

Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD

Blood (2014) 124 (21): 3094.

https://doi.org/10.1182/blood.V124.21.3094.3094

Published: 2014

Journal Articles

Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,

Jostein Dahle, PhD, Ada Repetto, Camilla Sivertsen Mollatt, Katrine Brustad Melhus, Øyvind Sverre Bruland, MD, PhD, Arne Kolstad, MD, PhD, Roy Hartvig Larsen, PhD

Blood (2011) 118 (21): 3732.

https://doi.org/10.1182/blood.V118.21.3732.3732

Published: 2011

Journal Articles

Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate

Jostein Dahle, Jørgen Borrebæk, Thora J. Jonasdottir, Anne Kristine Hjelmerud, Katrine B. Melhus, Øyvind S. Bruland, Oliver W. Press, Roy H. Larsen

Blood (2007) 110 (6): 2049–2056.

https://doi.org/10.1182/blood-2007-01-066803

Published: 2007

NARROW

NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies

B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Combination of 177 lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma

The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177 lu-Satetraxetan-Lilotomab

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,

Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only